Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK)Â is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
912 Views
BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns
Background - Eisai Co Ltd (4523 JP)Â on December 21, 2017, announced that 12 months data on BAN2401 did not meet its primary endpoint (link),...
565 Views
Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY19
We upgrade Eisai Co Ltd (4523 JP) to “Equal-weight” after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...
368 Views
A Conversation with Biogen
Biogen Inc (BIIB US) is Samsung Biologics Co., Ltd (207940 KS) 's minority (5.4%) partner in the Samsung Bioepis JV that manufactures and sells...
477 Views
Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset
On 12 March 2018, Biogen Inc (BIIB US) announced an agreement to acquire Pfizer Inc (PFE US)'s first-in-class, Phase 2b ready AMPA receptor...
331 Views